210 related articles for article (PubMed ID: 34962561)
1. Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.
Harper C; Mafham M; Herrington W; Staplin N; Stevens W; Wallendszus K; Haynes R; Landray MJ; Parish S; Bowman L; Armitage J
JAMA Netw Open; 2021 Dec; 4(12):e2139748. PubMed ID: 34962561
[TBL] [Abstract][Full Text] [Related]
2. Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.
Harper C; Mafham M; Herrington W; Staplin N; Stevens W; Wallendszus K; Haynes R; Landray MJ; Parish S; Bowman L; Armitage J
Heart; 2023 Sep; 109(19):1467-1472. PubMed ID: 37270201
[TBL] [Abstract][Full Text] [Related]
3. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.
Farrant M; Easton JD; Adelman EE; Cucchiara BL; Barsan WG; Tillman HJ; Elm JJ; Kim AS; Lindblad AS; Palesch YY; Zhao W; Pauls K; Walsh KB; Martí-Fàbregas J; Bernstein RA; Johnston SC
JAMA Netw Open; 2019 Sep; 2(9):e1910769. PubMed ID: 31490536
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Gaba P; Bhatt DL; Dagenais GR; Bosch J; Maggioni AP; Widimsky P; Leong D; Fox KAA; Yusuf S; Eikelboom JW;
JAMA Netw Open; 2022 Nov; 5(11):e2243201. PubMed ID: 36409491
[TBL] [Abstract][Full Text] [Related]
6. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
N Engl J Med; 2018 Oct; 379(16):1540-1550. PubMed ID: 30146932
[TBL] [Abstract][Full Text] [Related]
7. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
Aung T; Haynes R; Barton J; Cox J; Murawska A; Murphy K; Lay M; Armitage J; Bowman L;
Trials; 2016 Jun; 17(1):286. PubMed ID: 27296091
[TBL] [Abstract][Full Text] [Related]
8. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
Bowman L; Mafham M; Stevens W; Haynes R; Aung T; Chen F; Buck G; Collins R; Armitage J;
Am Heart J; 2018 Apr; 198():135-144. PubMed ID: 29653635
[TBL] [Abstract][Full Text] [Related]
9. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931
[TBL] [Abstract][Full Text] [Related]
10. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
Fowkes FG; Price JF; Stewart MC; Butcher I; Leng GC; Pell AC; Sandercock PA; Fox KA; Lowe GD; Murray GD;
JAMA; 2010 Mar; 303(9):841-8. PubMed ID: 20197530
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
[TBL] [Abstract][Full Text] [Related]
13. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Sugawara M; Goto Y; Yamazaki T; Teramoto T; Oikawa S; Shimada K; Uchiyama S; Ando K; Ishizuka N; Murata M; Yokoyama K; Uemura Y; Ikeda Y;
Am J Cardiovasc Drugs; 2019 Jun; 19(3):299-311. PubMed ID: 30565155
[TBL] [Abstract][Full Text] [Related]
14. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
[TBL] [Abstract][Full Text] [Related]
15. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid AS; Brown TJ; Brainard JS; Biswas P; Thorpe GC; Moore HJ; Deane KH; Summerbell CD; Worthington HV; Song F; Hooper L
Cochrane Database Syst Rev; 2020 Feb; 3(3):CD003177. PubMed ID: 32114706
[TBL] [Abstract][Full Text] [Related]
17. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
Aung T; Halsey J; Kromhout D; Gerstein HC; Marchioli R; Tavazzi L; Geleijnse JM; Rauch B; Ness A; Galan P; Chew EY; Bosch J; Collins R; Lewington S; Armitage J; Clarke R;
JAMA Cardiol; 2018 Mar; 3(3):225-234. PubMed ID: 29387889
[TBL] [Abstract][Full Text] [Related]
18. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
19. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
; Baigent C; Blackwell L; Collins R; Emberson J; Godwin J; Peto R; Buring J; Hennekens C; Kearney P; Meade T; Patrono C; Roncaglioni MC; Zanchetti A
Lancet; 2009 May; 373(9678):1849-60. PubMed ID: 19482214
[TBL] [Abstract][Full Text] [Related]
20. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
Zheng SL; Roddick AJ
JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]